11th International Conference on Cancer-Induced Bone Disease (CIBD)
Program and Speakers as of August 4, 2011
Wednesday November 30, 2011
3:30 Opening/Welcome Remarks
3:45pm – 5:00pm IMAGING PROGRAM
Patricia Keely – University of Wisconsin, Madison, WI, USA
Gabri van der Pluijm – Leiden University Medical Center, Leiden, the Netherlands
Vasilis Ntziachristos, Institute for Biological and Medical Imaging, Germany
Illuminating Biological Processes with Multi-spectral Optoacoustic Tomography (MSOT)
5:00pm – 5:20pm: Imaging short talks
Benjamin Hoff – University of Michigan, USA
Multi-Modality Imaging of Treatment Response in a Mouse Bone Metastatic Model of Breast Cancer
Julie Sterling - VA Medical Center/Vanderbilt University, USA
Novel TSPO PET Imaging Probes for Early Detection of Tumors in Bone
5:30pm – 8:00pm Welcome Reception
END DAY ONE
December 1, 2011
8:45 – 9:45: Cancer Stem Cells (Metastasis and Cancer Therapy)
Norman Maitland - University of York, York, United Kingdom
Gene Expression in Human Prostate Cancer: Stem Cells and Metastases
Margaret Read - Infinity Pharmaecuticals, Inc., Cambridge, MA, USA
Direct Targeting of Tumor Cells with the Smoothened inhibitor IPI-926
9:45 – 10:45: Non-coding RNAs and Cancer long non-coding RNAs and microRNAs
Andrea Ventura - Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Aurora Esquela Kerscher – Eastern Virginia Medical School, Norfolk, VA, USA
From Worms to Humans: Understanding the Role of MicroRNAs in Cancer Progression
10:45 – 11:15: Short Talks 1
Cancer Stem Cells (Metastasis and Cancer Therapy)
Huiping Liu – University of Chicago, USA
Identification of miRNAs that Regulate Breast Cancer Stem Cells and Spontaneous Metastases in Orthotopic Xenograft Models
Non-Coding RNAs and Cancer (Long non-coding and Mirco RNAs)
Xijie Yu – Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan University, China
miR-335 and miR-29a Regulate Bone Metastasis in Lung Cancer
Croset Martine – Faculte Laennec UMR1033, France
MicroRNAs-30 Family Regulates Breast Cancer Bone Metastasis Formation
11:15 – 11:30: BREAK
11:30 – 12:30: Premetastatic Niche
Janine Erler - Institute of Cancer Research, Sutton, Surrey, United Kingdom
Lysyl Oxidases in Pre-metastatic Niche Formation and Bone Metastases
David Lyden - Cornell University Medical School, New York, NY, USA
12:30 – 2:00: Lunch and Posters
2:00 – 3:00: Disseminated Tumor Cell Tumor Dormancy
Yibin Kang - Princeton University, Princeton, NJ, USA
VCAM1 Activates Dormant Bone Metastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast Progenitors
Klaus Pantel- University Medical Center (UKE), Hamburg, Germany
Circulating Tumor Cells, Bone Marrow Micrometastasis and Cancer Dormancy
3:00 – 3:30: Invasion and Metastasis
Erik Thompson - St Vincent's Institute of Medical Research,Fitzroy, Victoria, Australia
Epithelial Mesenchymal Plasticity in Breast Cancer Metastasis
3:30 – 4:00: Short Talks 2
Premetastatic Niche
Rachelle Johnson - Vanderbilt University Medical Center, USA
Bone Stiffness Drives Wnt Signaling Regulation of Gli2 in Osteolytic Breast Cancer Cells
J. Preston Campbell – Vanderbilt University, USA
Chronic Stress Increases Spontaneous Breast Cancer Metastasis to Bone Which Can Be Rescued with Propranolol
Invasion and Metastasis
Nyam-Osor Chimge – University of Southern California Keck School of Medicine, USA
Regulation of Breast Cancer Metastasis by Runx2 and Estrogen Signaling: Role of SNAI2
4:00 – 4:20: BREAK
4:20- 4:50: Epithelial-mesenchymal transition
John Condeelis - Albert Einstein College of Medicine, Bronx, NY, USA
Tumor Microenvironments of Dissemination and Metastasis
6:00 – 7:30: Curatio Dinner Symposium
A CME-certified satellite symposium to be held in conjunction with the 11th International Conference on Cancer-Induced Bone Disease
Advancing the Management of Cancer-Related Bone Disease
Bone is the most common site of cancer metastasis, and bone metastases are often involved in advanced breast and prostate cancer. Fractures are a serious consequence of bone metastases, as well as predictors of poor survival in cancer. This symposium focuses on the current state of the art in the treatment and prevention of cancer-related bone loss, fracture, and bone metastases, and also features a discussion on how the pathophysiology of bone disease is informing the development of new and emerging therapies.
END OF DAY TWO
December 2, 2011
8:30-9:30: Molecularly Targeted Therapies
Russ Taichman - University of Michigan Dental School, Ann Arbor, MI, USA
The Hematopoietic Stem Cell Niche is the Target of Metastatic Cells from Solid Tumors
Laurie McCauley - University of Michigan Dental School, Ann Arbor, MI, USA
Bone Marrow Derived Myeloid Cells Set the Stage for Prostate Cancer (PCa) Skeletal Metastasis
9:30 - 10:10: Short Talks 3
Molecularly Targeted Therapies
Majd Zayzafoon – The University of Alabama at Birmingham, USA
The Role of S100A4/RAGE Signaling in Prostate Cancer Bone Metastasis
Jacqueline Akech - University of Massachusetts Medical School, USA
Runx2 as a Prognostic Factor in Prostate Cancer Patients and the Potential for Therapies Inhibiting Tumor Progression
Fernando Lecanda – Center for Applied Medical Research, Spain
APC/EPCR Signaling Promotes Survival and Bone Metastasis in Lung Adenocarcinoma
Albert Rhee – Amgen Inc
Denosumab Extends Bone Metastasis-Free Survival in Men With Castrate-Resistant Prostate Cancer: Results of a Global Phase 3, Randomized, Double-Blind Trial
10:10 – 10:30: BREAK
10:30 – 11:30: Translating Trial Results into Clinical Practice
Rob Coleman - University of Sheffield, United Kingdom
Prevention of Metastasis. Does Treating the Soil Influence the Seed?
Matthew Smith - Harvard Medical School, Cambridge, MA, USA
11:30-12:00: Short Talks 4
Translating Trial Results into Clinical Practice
Vahid Entezari – Beth Israel Deaconess Medical Center, USA
CT-based Rigidity Analysis Affects Treatment Plan for Appendicular Skeletal Metastasis
G. Morgan - The Institute of Cancer Research, United Kingdom
Insights Into the Mechanisms Underlying Zoledronic Acid (ZOL) Overall Survival (OS) Benefits Versus Clodronate (CLO): Subgroup Analyses by Baseline Demographics and Disease Characteristics
Robert Coleman - University of Sheffield, United Kingdom
Is Inhibiting the “Vicious Cycle” always beneficial? Discordant Treatment Effects By Menopausal Status on Extra-skeletal Recurrence in the AZURE (BIG01/04) Trial.
12:00 – 1:30: Lunch and Posters
1:30-2:30: Therapy Resistance
Jos Jonkers - Netherlands Cancer Institute, Amsterdam, the Netherlands
Studying Therapy Response and Resistance in genetically Engineered Mouse Models of Human Breast Cancer
Stephen Hiscox - Welsh School of Pharmacy, Cardiff University, Wales, United Kingdom
Exploiting Therapeutic Resistance Mechanisms to Limit Bone Disease in Breast Cancer
2:30-3:30: Anabolic Agents
Evan Keller - University of Michigan Medical School, Ann Arbor, MI, USA
Wnts in Bone Metastasis
Noopur Raje - Massachusetts General Hospital, Cancer Center, Boston, MA, USA
3:30-3:45: BREAK
3:45-4:15: Late Breaking Abstracts short talks (3)
4:15 – 5:45: Debate: the Merits of Bisphosphonates and Denosumab to Treat Bone Mets
Moderator: David Roodman
Panel: Michael Gnant, Rob Coleman, Matt Smith, Allan Lipton
End of day Three
December 3, 2011
8:30 – 10:00: IBMS-BONE Session: Primary Bone Tumors
Piero Picci - Bone Tumor Center, Istituto Ortopedico Rizzoli Via di Barbiano, Barbiano, Italy
New Strategies for Treatement of Primary Bone Tumors
Gonzague de Pinieux - Hôpital Trousseau, Tours, France
Assessment of MDM2 Protein Expression and Gene Amplification is a Valuable Tool in the Differential Diagnosis of Low-grade Osteosarcomas and Other Primary Mimicking Benign Lesions of the Bone
Annemarie Clenton-Jansen – Leiden University Medical Center, Leiden, the Netherlands
10:00 – 10:30: Short Talks 5
Primary Bone Tumors
Michelle Hurchla – Washington University School of Medicine, USA
The ARF Tumor Suppressor Pathway is a Key Regulator of Bone Remodeling and Osteosarcoma Development in Mice
Masahiro Abe – University of Tokushima, Japan
An Acidic Milieu Aggravates Myeloma Growth And Drug Resistance But Triggers Anti-myeloma Activity Of Reveromycin A, A Novel Anti-resorptive Agent
Tumor Associated Stroma
Rebecca Silbermann – University of Pittsburgh
Activin A Mediates the Osteoclastogenic Effects of IL-3 in Multiple Myeloma
10:30-11:00: BREAK
11:00 – 11:30: Tumor-associated Stroma
Marco G Cecchini - University of Berne, Berne, Switzerland
Molecular Characterization of the Stromal Reaction in Mouse Xenograft Models of Prostate Cancer Bone Metastasis
11:30 – 12:10 Short Talks 6
Tumor-associated Stroma
Michelle Hurchla - Washington University School of Medicine, USA
Hedgehog Signaling Inhibition Blocks Growth of Resistant Tumors Through Effects on the Tumor Microenvironment
Xiaohong Li - Vanderbilt University, USA
Breast cancer-Induced Osteolytic Bone Lesions are Promoted by TGF-β Signaling in Osteoblasts, but Inhibited When Targeted to Osteoclasts
Aude-Helene Capietto - Washington University School of Medicine, USA
Myeloid Derived Suppressor Cells are New Players in the Tumor Bone Vicious Cycle and Enhance Bone Tumor Growth in Osteopetrotic PLCγ;2-/- Mice
Serk In Park - University of Michigan, USA
Potentiation of Myeloid-Derived Suppressor Cells (MDSCs) within the Bone Marrow by Tumor-Derived Parathyroid Hormone-related Peptide (PTHrP)
12:10 – 12:30: Meeting Wrap-up